ABtest-IA is a colorimetric sandwich ELISA that requires 300 microliters of plasma for the determination of Aβ40 and Aβ42.
Because of its capacity to analyse large numbers of samples in a short time and at low cost, ABtest-IA is particularly suitable for the study of previously stored specimen collections.
Analytical Validation
The assay is fully validated from an analytical point of view according to EMA and FDA recommendations and is CE marked in the European Union and Investigational Research Only (IUO) in the rest of the world.
Clinical Results
The plasma Aβ42/Aβ40 ratio has been predictive of Amyloid-PET status, with areas under the ROC curve ranging from 0.77 to 0.88 in different cohorts (0.78 to 0.96 when the APOE genotype is included in the predictor model).
Recruitment Hypothetical Scenario
In a hypothetical recruitment scenario for a clinical trial of cognitively healthy individuals with confirmed amyloid brain pathology, pre-screening with ABtest would save up to 60% of the required amyloid PET scans (or CSF analysis).
Our services
ABtest-Service
The safest way to obtain reliable results from automated analysis under strictly standardised conditions and performed by highly qualified personnel.
ABtest-MS
Service for the determination of Aβ42 and Aβ40 peptides in plasma by liquid chromatography tandem mass spectrometry assay patented by Araclon Biotech.
COMPLETE ANALYTICAL VALIDATION
How can we help you?
Contact the Araclon Biotech team.